Dr. Carignan brings extensive clinical, product development, commercialization, and leadership expertise to the role. He has served on committees of the U.S. Food and Drug istration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Additionally, he has led multiple successful corporations, including being the founding president and CEO of NinePoint Medical, president and CEO of BionX Medical, and CEO of SoniVie Inc. Additional prior roles include executive vice president and chief medical officer at Novasys Medical, chief medical officer of Endosurgery at Boston Scientific, and vice president of clinical research and medical affairs at Conceptus, Inc. He currently serves as the executive chairman of Cairdac, chairman of SamanTree Medical, and a director of Biothea and Prothea.
“It is a privilege to welcome Chuck to Anaconda Biomed,” said Trent Reutiman, chief executive officer. “With his leadership experience at Boston Scientific, numerous private venture-backed start-ups, and international government health agencies, Chuck brings a proven track record of developing and overseeing global healthcare companies. His operational and clinical insights will be invaluable as we continue to grow.”
Dr. Carignan is ing the company at a critical time as enrollment progresses in the global investigational device exemption (IDE) ATHENA clinical trial, and additional work continues on building the company’s pipeline of products.
Dr. Carignan added, “Beginning with the unique ANA Funnel Catheter technology, Anaconda has the opportunity to literally change the shape of the mechanical thrombectomy field. I am honored to the board to actively contribute to the next phase of the company’s successes by working closely with Trent and the rest of the board.”
Be the first to comment 3t5h3u